In 2022, Chinese investments and acquisitions in Switzerland totaled 96 million US dollars, approximately 610 million RMB, with three concentrated in healthcare and two in consumer goods and services, a 13-fold increase from 2020's 7 million US dollars.

Switzerland ranks among the world's most advanced regions in medical technology and holds the largest trade surplus in pharmaceuticals globally, with over one-third of its total exports coming from the pharmaceutical industry. Switzerland's investment in the biotechnology industry is equivalent to 40% of Europe's total.

Last year, Europe surpassed the United States for the first time, becoming the region with the most financing for Chinese companies going public. Specifically, five Chinese companies raised over 2.1 billion US dollars through listings on exchanges in Zurich and London. In the United States, only eight companies went public, raising a total of 230 million US dollars, a 98.2% decrease from the previous year. The number of newly issued shares hit a three-year low, with a total fundraising amount of 70.2 billion US dollars, down 49.8% year-on-year.